Suppr超能文献

三级医疗中心德尔塔变异株激增期间接种疫苗与未接种疫苗个体的新冠严重程度和死亡率比较分析:一项队列研究

Comparative Analysis of COVID-19 Severity and Mortality Among Vaccinated and Unvaccinated Individuals During the Delta Variant Surge in a Tertiary Care Center: A Cohort Study.

作者信息

Hasani Fatemeh, Norouzi Zahra, Jazi Kimia, Roshandel Gholamreza, Norouzi Alireza

机构信息

Golestan Research Center of Gastroenterology and Hepatology Golestan University of Medical Sciences Gorgan Iran.

Student Research Committee, Faculty of Medicine Qom University of Medical Sciences Qom Iran.

出版信息

Health Sci Rep. 2025 Jan 16;8(1):e70346. doi: 10.1002/hsr2.70346. eCollection 2025 Jan.

Abstract

BACKGROUND AND AIMS

On March 11, 2020, the World Health Organization declared Coronavirus disease 2019 (COVID-19) as a pandemic. The spread of the Delta variant of coronavirus started in June 2021 and accounted for the fifth peak of COVID-19 in Iran in July 2021. According to reports from other countries, vaccination protects against severe diseases caused by COVID-19, including the Delta variant. Studies have also shown that vaccination provides strong protection against SARS-CoV-2 infection, COVID-19-related hospitalization, and mortality. This retrospective cohort study was designed based on the medical care monitoring center database of Sayyad Shirazi Hospital.

METHODS

COVID-19 confirmed patients' data were extracted for this study from June 22, 2021, to September 22, 2021 including demographic characteristics, signs and symptoms, ICU admission, need for aggressive oxygen therapy, including intubation, mortality, and vaccination status.

RESULTS

A total of 2962 patients were enrolled. Being vaccinated was associated with a 4.14-fold increase in survival (adjusted OR = 4.14; 95% CI: 2.22-7.69;  < 0.01), and individuals in a younger age group demonstrated a 5.58-fold higher likelihood of surviving (adjusted OR = 5.58; 95% CI: 4.25-8.14;  < 0.01). The risk of severe COVID-19 was significantly lower in vaccinated individuals, showing a 3.12-fold decrease in risk (adjusted OR = 3.12; 95% CI: 2.06-4.72;  < 0.01), and in younger age groups, the risk exhibited a 3.28-fold decrease (adjusted OR = 3.28; 95% CI: 2.66-4.04;  < 0.01).

CONCLUSION

The present results suggest that receiving at least one dose of COVID-19 vaccine had a significant relationship with decreased COVID-19 severity and mortality in vaccinated patients compared to unvaccinated patients.

摘要

背景与目的

2020年3月11日,世界卫生组织宣布2019冠状病毒病(COVID-19)为大流行病。冠状病毒德尔塔变异株于2021年6月开始传播,并导致了2021年7月伊朗COVID-19的第五波高峰。根据其他国家的报告,接种疫苗可预防由COVID-19引起的严重疾病,包括德尔塔变异株。研究还表明,接种疫苗可为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染、COVID-19相关住院治疗和死亡提供强有力的保护。这项回顾性队列研究是基于赛义德·希拉齐医院的医疗监测中心数据库设计的。

方法

本研究提取了2021年6月22日至2021年9月22日期间COVID-19确诊患者的数据,包括人口统计学特征、体征和症状、入住重症监护病房(ICU)情况、是否需要包括插管在内的积极氧疗、死亡率以及疫苗接种状况。

结果

共纳入2962例患者。接种疫苗与生存率提高4.14倍相关(调整后的比值比[OR]=4.14;95%置信区间[CI]:2.22-7.69;P<0.01),且年龄较小的患者组生存可能性高5.58倍(调整后的OR=5.58;95%CI:4.25-8.14;P<0.01)。接种疫苗的个体发生重症COVID-19的风险显著较低,风险降低3.12倍(调整后的OR=3.12;95%CI:2.06-4.72;P<0.01),在年龄较小的患者组中,风险降低3.28倍(调整后的OR=3.28;95%CI:2.66-4.04;P<0.01)。

结论

目前的结果表明,与未接种疫苗的患者相比,接种至少一剂COVID-19疫苗与接种疫苗患者的COVID-19严重程度降低和死亡率降低显著相关。

相似文献

本文引用的文献

4
Exploring the experience of developing COVID-19 vaccines in Iran.探索伊朗研发新冠疫苗的经历。
Clin Exp Vaccine Res. 2023 Jan;12(1):1-12. doi: 10.7774/cevr.2023.12.1.1. Epub 2023 Jan 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验